Analyst Price Targets — PCVX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 7:27 pm | Tom Shrader | BTIG | $89.00 | $63.04 | StreetInsider | Vaxcyte (PCVX) PT Raised to $89 at BTIG |
| November 19, 2025 10:23 am | David Risinger | Leerink Partners | $77.00 | $49.53 | StreetInsider | Vaxcyte (PCVX) PT Raised to $77 at Leerink Partners |
| November 6, 2024 11:13 am | Roger Song | Jefferies | $146.00 | $106.74 | StreetInsider | Vaxcyte (PCVX) PT Raised to $146 at Jefferies |
| November 6, 2024 10:59 am | David Risinger | Leerink Partners | $135.00 | $106.74 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX) |
| September 10, 2024 6:46 am | Salim Syed | Mizuho Securities | $163.00 | $115.28 | TheFly | Vaxcyte price target raised to $163 from $113 at Mizuho |
| September 4, 2024 6:34 am | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | TheFly | Vaxcyte price target raised to $140 from $101 at BofA |
| September 3, 2024 2:34 pm | David Risinger | Leerink Partners | $153.00 | $112.04 | TheFly | Vaxcyte price target raised to $153 at Leerink after VAX-31 'home run' |
| September 3, 2024 11:48 am | Tom Shrader | BTIG | $160.00 | $110.15 | StreetInsider | Vaxcyte (PCVX) PT Raised to $160 at BTIG |
| September 3, 2024 9:33 am | Roger Song | Jefferies | $129.00 | $111.13 | StreetInsider | Vaxcyte (PCVX) PT Raised to $129 at Jefferies |
| September 3, 2024 8:25 am | Salim Syed | Mizuho Securities | $113.00 | $111.09 | StreetInsider | Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX) |
Latest News for PCVX
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21) and Prevnar 20® (PCV20), the Current Standard-of-Care PCVs
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 Pivotal Noninferiority Trial Expected in the Fourth Quarter of 2026
Bridgefront Capital LLC boosted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 127.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,325 shares of the company's stock after buying an additional 13,617 shares during the period. Bridgefront Capital
Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 313,078 shares of the company's stock after selling 116,206 shares during the period. Citigroup Inc. owned approximately 0.24% of Vaxcyte worth $11,277,000 as
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCVX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.